Investors at a FundingPost Venture Event Investors at a FundingPost Venture Event Investors at a FundingPost Venture Event Investors at a FundingPost Venture Event Investors at a FundingPost Venture Event
Venture Capital
** Click Here to Register for our next Early-Stage VC & Angel Investor events:
  • Dallas VC & Angel Roundtable Nov 2
  • Philly VC & Angel Roundtable Dec 5
  • Houston VC & Angel Roundtable Dec 6
  • DC VC & Angel Roundtable Dec 7
  • Vegas VC & Angel Roundtable March 29
  • Phoenix VC & Angel Roundtable May 17


  • Here are the Investor speakers from our Sold-Out Life Sciences Venture Breakfast, sponsored by PriceWaterhouse Coopers, Thelen Reid & Preist, LLP, Fairleigh Dickinson University. This event was in New Jersey on November 7, 2006.

    Phillip P. Chan M.D., Ph.D., Associate, NJTC Venture Fund Phillip P. Chan M.D., Ph.D., Associate, NJTC Venture Fund

    Phillip leads investments in the healthcare, medical device, and biotechnology sectors. He received his MD and PhD in Genetics from the Yale University School of Medicine where he helped pioneer new advances in oligonucleotide-based gene therapy. Phillip completed his Internal Medicine residency at the Beth Israel Deaconess Medical Center at Harvard and is a Board-certified Internal Medicine physician. He also holds a BS in cell and molecular biology from Cornell University, graduating with honors and distinction.

    Zubeen Shroff, Managing Director, Galen Partners Zubeen Shroff, Managing Director, Galen Partners

    Mr. Shroff joined Galen in 1997 from The Wilkerson Group, where he was a principal with a client base including pharmaceutical, diagnostics, device and biotech companies, plus a select number of venture capital firms.

    He also played a major role in developing several of the firm's practice areas, including outcomes research, strategy formulation, and disease management initiatives. Prior to joining The Wilkerson Group, Mr. Shroff worked at Shering-Plough France, where he directed the marketing and Phase IV clinical development of the company’s high-growth biotech business.

    Mr. Shroff received a BA in Biological Sciences from Boston University and an MBA from the Wharton School. Additionally, he is an Executive Committee Member of Boston University’s Medical School Advisory Board and is a member of the Westchester Medical Center Foundation Board.

    Conrad Everhard, of Counsel, Thelen Reid & Preist, LLP Conrad Everhard, of Counsel, Thelen Reid & Preist, LLP

    Mr. Everhard focuses his practice on counseling high growth and technology-driven companies in all aspects of their business and legal needs, including start-up formation, venture capital, private equity, technology M&A transactions, IP portfolio protection, strategic partnering, licensing, technology transfers and executive compensation. Mr. Everhard also assists emerging companies in structuring financing transactions, evaluating funding sources and crafting business plans that maximize the opportunity to successfully commercialize their technology products and services.

    As the leader of the firm's New Jersey based emerging companies and technology transactions practice, Mr. Everhard counsels entrepreneurial companies, financial investors and strategic corporate investors, and venture capital, mezzanine, hedge and private equity funds in all aspects of the exploitation, financing, marketing and commercialization of technology and IP assets.

    Mr. Everhard applies over fifteen years of industry-specific experience to devise practical and cost effective business solutions to complex transactions. He effectively leverages the Firm's deep roots in Silicon Valley, strategic locations in major centers of commercial activity, and nationally recognized technology IP practice, to offer our New Jersey and Mid-Atlantic based clients the full multi-disciplinary resources of a technology sector focused national firm.

    Prior to joining Thelen Reid & Priest LLP, Mr. Everhard was a partner in the New York City office of a large international law firm, where he practiced on the venture capital and M&A teams.

    Chris Starr, Vice President, Science Center Chris Starr, Vice President, Science Center

    Christopher Starr is a Vice President of Investments at the Science Center, responsible for the management of Science Center Capital, a venture capital fund targeting seed and early stage technology and life science investments in the Greater Philadelphia region.

    Additionally, Mr. Starr is the Executive Director and Founder of the Mid-Atlantic Angel Group Fund, I L.P. (MAG), the largest angel group and first structured angel fund in the Mid-Atlantic region. The MAG Fund has over $4.4 million under management and includes 89 institutional and individual accredited investors Mr. Starr is responsible for all aspects of administration and operations of the Fund and is the primary contact for both entrepreneurs and the funding community for the Fund’s membership.

    Most recently, Mr. Starr was the Managing Director and Vice President of Investments at Innovation Philadelphia. At Innovation Philadelphia, Mr. Starr is responsible for all of the company’s investment programs. His responsibilities include executing economic stimulus investments, attracting new companies to the region, evaluating potential investment opportunities, performing due diligence, negotiating and structuring investments, and working with portfolio company management teams to execute their strategies.

    Additional Investor speakers to be announced! Additional Investor speakers to be announced!



    Moderator: Susan Roos, PriceWaterhouse Coopers

    ADODB.Recordset error '800a0cc1'

    Item cannot be found in the collection corresponding to the requested name or ordinal.

    /breakfast/bios.asp, line 1375